In Situ Hybridization Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

In situ hybridization market research study shows the market shares and forecasts through 2024. These markets are set to grow significantly.

The 2018 study In Situ Hybridization Market has 242 pages, 83 tables and figures. Worldwide markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.

Complete Report available at

In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).

Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions.

Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.

Get Discount on this Research Report at

In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations—the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target—the difference is the greater amount of information gained by visualizing the results within the tissue.
The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

Order a Copy of this Research report at

Companies Profiled
Market Leaders
• Leica Biosystems Nussloch GmbH
• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Agilent Technologies
• PerkinElmer
• Qiagen / Exiqon A/S
• Merck KGaA
• BioGenex Laboratories
• BioTechne / Advanced Cell Diagnostics (ACD)

Key Topics
• In Situ Hybridization
• Molecular Diagnostics
• Cervical Cancer Stain
• Fish Steps Reduction
• Fluorescence In Situ Hybridization (FISH)
• In Situ Hybridization (ISH)
• FISH Probe Kit
• Cancer
• Chromosonal Abnormalities
• Infectious Diseases
• Inflammatory Diseases
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Human Genetic Tests
• Microbial Tests
• In Vitro Diagnostics
• System for the Analysis of Solid Tumors
• Hybridization Technique
• Detection of Long Non-
• Coding DNA
• Coding RNA

Table of Contents:
US In situ Hybridization Executive Summary
In Situ Hybridization (ISH)

1. United States In Situ Hybridization ISH Market Definition and Market Dynamics
2. In-Situ Hybridization Market Shares and Market Forecasts
3 In-Situ Hybridization Research and Technology
4 In-Situ Hybridization Company Profiles
5 Summary and Conclusions
6 Appendix A: List Of Nucleic Acid-Based Tests

List of Figures.

Contact Info:
Name: Hrishikesh Patwardhan
Email: Send Email
Organization: ReportsnReports
Address: 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001
Phone: + 1 888 391 5441

Release ID: 316452